Choose a technique because it answers the decision
Analytical work can range from simple identification to extensive data interpretation, method development, chemical composition analysis, contaminant or residue analysis, complex structure analysis, and solid-state phase analysis.
The correct technique is not the most sophisticated one; it is the method that can distinguish the failure modes that matter. A good analytical plan states the decision, the sample constraints, the expected matrix interferences, the regulatory context, and what would count as a defensible conclusion.
What FDA and quality reviewers care about across techniques
For regulated pharmaceutical work, FDA-facing data must be specific, scientifically justified, reproducible, and tied to the quality attribute being controlled. ICH Q2(R2) and Q14 are the relevant analytical-procedure framework for development and validation; elemental methods also need ICH Q3D/USP <232>/<233> logic where applicable.
Common mistakes include using a single technique as proof when orthogonal evidence is required, validating an easy matrix instead of the real product, ignoring sample history, under-documenting sample preparation, or reporting instrument output without explaining what decision the result supports.
What is Triclinic's experience with this technique
Triclinic applies analytical technique selection to real-world pharmaceutical and materials problems where one measurement is not enough to make a defensible decision. Typical uses include comparing lots, identifying solid form or composition changes, investigating failures, selecting orthogonal tests, and building data packages that support development, quality, and regulatory decisions. The practical value is in connecting structural, thermal, microscopic, spectroscopic, chromatographic, elemental, moisture, and particle-size evidence to a clear material conclusion.
Technical Resources and Publications
These examples include technical resources, regulatory guidances, or literature relevant to the technique. Download buttons are placed at the bottom-left of each example.
A Comprehensive Approach for Solid Form Selection in Preclinical Development and Beyond
Author: Melanie Bevill, Chris Seadeek, Nico Setiawan, Shawn Comella, Blaise Mibeck, and Steef Boerrigter
Publication date: November 2023
Abstract: This Triclinic application note links solid-form screening and selection to crystallinity, stability, solubility, hygroscopicity, manufacturability, regulatory needs, and IP objectives. It supports choosing analytical techniques based on the development decision rather than a fixed instrument list.
Download
ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: FDA notes that ICH Q2(R2) and Q14 describe validation and development principles for analytical procedures used to assess drug substance and drug product quality. These guidances frame FDA expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence.
Download
ICH Q3D(R2) Guideline for Elemental Impurities
Author: International Council for Harmonisation
Publication date: 2022
Abstract: ICH Q3D(R2) provides the risk-management framework for assessing and controlling elemental impurities in drug products. It is the regulatory anchor for elemental-impurity testing, method selection, and justification of ICP-MS, XRF, or other elemental-analysis strategies.
Download
Use this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View technique
Discuss the right analytical technique
Tell Triclinic what sample you have, what decision the data must support, what prior data are available, and whether cGMP, release, validation, or regulatory documentation is required.
